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. Although MeCP2 is expressed in most tissues 2 , loss of MeCP2 expression results primarily in neurological symptoms 1, 3, 4 . Earlier studies suggested the idea that RTT is due exclusively to loss of MeCP2 function in neurons 2, [4] [5] [6] [7] [8] [9] [10] . Although defective neurons clearly underlie the aberrant behaviours, we and others showed recently that the loss of MECP2 from glia negatively influences neurons in a non-cell-autonomous fashion [11] [12] [13] . Here we show that in globally MeCP2-deficient mice, re-expression of Mecp2 preferentially in astrocytes significantly improved locomotion and anxiety levels, restored respiratory abnormalities to a normal pattern, and greatly prolonged lifespan compared to globally null mice. Furthermore, restoration of MeCP2 in the mutant astrocytes exerted a non-cell-autonomous positive effect on mutant neurons in vivo, restoring normal dendritic morphology and increasing levels of the excitatory glutamate transporter VGLUT1. Our study shows that glia, like neurons, are integral components of the neuropathology of RTT, and supports the targeting of glia as a strategy for improving the associated symptoms.
Global re-expression of Mecp2 postnatally in MeCP2-deficient mice allows normal longevity, rescues motor behaviours and improves overall health 14 . Because the expression of Mecp2 from the neuronal tau locus in early development prevents the appearance of several RTT-like symptoms 9 , neurons are probably crucial components in a rescue. However, previous in vitro studies indicate that astrocytic MeCP2 supports normal neuronal morphology 11, 12 . Therefore, we asked whether astrocytes might also have a role in rescuing RTT neuropathology in vivo.
To this end, we crossed mice harbouring a tamoxifen (TAM)-inducible cre recombinase transgene driven by the human astrocytic glial fibrillary acidic protein (hGFAP) promotor 15 (also see refs [16] [17] [18] ) with mice containing a Cre-excisable transcriptional Stop sequence in the endogenous Mecp2 gene (Mecp2 Stop ) 14 . The progeny that inherited both alleles are referred to as Mecp2 Stop -hGFAPcreT2 mice (Supplementary Fig. 1a) . We determined the efficiency of astrocytic excision in ROSA-reporter 15 and Mecp2
Stop/y -hGFAPcreT2 mice (Supplementary 
GFAP
1 astrocytes was extremely high in caudal brain regions, similar to that of Mecp2 1/y mice ( Fig. 1a and Supplementary Fig. 1e ). Re-expression of Mecp2 was not detected in oil-treated Mecp2
Stop/y -hGFAPcreT2 mice ( Supplementary Fig. 2a) . Notably, only a very low percentage (,5%) of excision in neurons was detected by immunolabelling, polymerase chain reaction (PCR) analysis of the recombined Stop sequence, and single cell immunofluorescence intensity measurements ( Fig. 1 and Supplementary Figs 1f, g and 3) . This low percentage did not increase with age ( Supplementary Figs 1g and 4) , and Mecp2 re-expression was restricted to brain ( Supplementary Fig. 5c ). Overexpression of Mecp2 in rescued astrocytes was not observed ( Supplementary  Fig. 2b ). To rule out the possibility that the small percentage of neurons, in combination with the low constitutive level of MeCP2 in the Stop mice ( Supplementary Fig. 5b, c) , might mediate any behavioural changes that we would measure, we systemically injected young male Mecp2
Stop/y mice with a suboptimal titre of recombinant MeCP2-AAV9 virus 19 or virus lacking MeCP2. This resulted in physiological levels of MeCP2 expression in 2% to 35% of neurons, depending on the brain region ( Supplementary Fig. 6a-c) . Regardless of genotype, none of the treated mice showed improvement of RTT-like phenotypes compared to the control-AAV9-injected Mecp2 2/y mice ( Supplementary Fig. 6d-g ). Taken together, the results validate the use of the hGFAPcreT2 system for dissecting astrocytic contributions to RTT.
The average lifespan of oil-treated Mecp2
Stop/y -hGFAPcreT2 and Mecp2
Stop/y mice was only 3 months 14 , which is prolonged compared to Mecp2 2/y mice 3,4 ( Supplementary Fig. 5a ), and probably due to the small amount of MeCP2 protein expressed from the Stop locus ( Supplementary Fig. 5b, c) . In contrast, nine of eleven TAM-treated Mecp2
Stop/y -hGFAPcreT2 mice were alive at 7.5 months, when seven of the nine mice were killed for further analysis. The longest-lived mouse was killed at 15 months. The TAM-treated Mecp2
Stop/y -hGFAPcreT2 mice were also, on average, 20% larger than oil-treated Mecp2
Stop/y -hGFAPcreT2 mice ( Supplementary Fig. 7a ). Using a previously described observational scoring system 14 , overall health of the TAMtreated male ( Supplementary Fig. 7b ) and female ( Supplementary Fig. 8 ) mice stabilized, rather than worsened like the oil-treated controls, and TAM treatment of a highly symptomatic Mecp2
Stop/y -hGFAPcreT2 mouse reversed symptoms to nearly hGFAPcreT2 values (Supplementary Fig. 9 and Supplementary Movies 1 and 2 ).
MeCP2-deficient mice are hypoactive 1, 3, 4 and show altered measures of anxiety-related behaviours 6 . In the home cage (Fig. 2a, b ) and open field (Fig. 2c) Stop/y -hGFAPcreT2 mice again improved to ,50% the level of hGFAPcreT2 mice (Fig. 2d) . The ratio of distance travelled in the centre square to total distance was the same for all genotypes (data not shown). In the elevated zero and plus mazes, Mecp2 2/y mice consistently show decreased anxiety-related behaviour 20, 21 . The TAM-treated Mecp2
Stop/y -hGFAPcreT2 mice were more anxious than the oil-treated Mecp2
Stop/y -hGFAPcreT2 mice in the elevated zero maze, improving up to ,50% the level of the control hGFAPcreT2 mice (Fig. 2e) .
RTT patients and mouse models have abnormal respiration 1, 22 ( Fig. 3a) . By 12 weeks, Mecp2
Stop/y -hGFAPcreT2 mice had irregularity scores and apnoea rates significantly more severe than hGFAPcreT2 controls (Fig. 3a, b and Supplementary Fig. 7c , traces 1 and 2). In contrast, 2 months after TAM treatment, the respiratory pattern in 10 of 12 Mecp2
Stop/y -hGFAPcreT2 mice was within the normal range (Fig. 3b) . Two mice followed over the subsequent 5-month period maintained regular breathing patterns (data not shown). In two of three TAMtreated mice, we observed complete reversal to a normal respiratory pattern ( Fig. 3a and Supplementary Fig. 7c , traces 3 and 4). The apnoeic frequency in the third mouse was reduced but did not completely revert to control levels ( Supplementary Fig. 7c , trace 5). The improvement in respiration was consistent with efficient re-expression of Mecp2 in GFAP 1 astrocytes within the pre-Bötzinger complex of the brainstem, an area implicated in respiratory defects in RTT 23 ( Supplementary  Fig. 7e ). Treatment of a Mecp2
Stop/y mouse with TAM did not alleviate the irregular breathing or apnoeic frequency ( Supplementary Fig. 7c , trace 2). Oil-treated female Mecp2
1/Stop
-hGFAPcreT2 mice developed a significant number of apnoeas beginning at 4-6 months (Fig. 3c) . The apnoeic breathing was corrected by TAM treatment (Fig. 3c) , even in the most severely affected female mouse ( Supplementary Fig. 7d ).
The brains of girls with RTT and affected mice exhibit smaller neuronal somal sizes and reduced dendritic complexity in some regions 1, 4, 24, 25 . At ,3.5 months of age, the somal sizes of neurons in hippocampus, cerebellum and cortex were still smaller in TAM-treated Mecp2
Stop/y -hGFAPcreT2 mice compared to hGFAPcreT2 controls. At 7 months, however, somal size was restored only in brain regions showing astrocytic re-expression of Mecp2 (Fig. 4a) . Regarding dendritic complexity, the Mecp2
Stop/y and oil-treated Mecp2
Stop/y -hGFAPcreT2 mice had ,25% less total number of apical dendrite branches compared to controls. By 3.5 months of age, however, neurons in TAM-treated Mecp2
Stop/y -hGFAPcreT2 mice had a normal number of branches and this was sustained with further age (Fig. 4b, c) . MeCP2-deficient neurons also show deficits in proteins necessary for excitatory neurotransmission, such as VGLUT1 (refs 26, 27) . We detected ,20% less peri-nuclear VGLUT1 1 puncta in Mecp2 Stop/y and oil-treated Mecp2
Stop/y -hGFAPcreT2 mice compared to controls, but the levels increased to normal by 3-4 months of age with TAM treatment of Mecp2
Stop/y -hGFAPcreT2 mice (Fig. 4d, e) . Taken together, the anatomical findings indicate that re-expression of Mecp2 in astrocytes can, through a non-cell-autonomous mechanism, positively influence components of the neurotransmission machinery in vivo.
Our results show that re-expression of Mecp2 in astrocytes ameliorates overt RTT-like phenotypes in mice. To address the complementary question of the consequences of the removal of MeCP2 from astrocytes, we crossed mice with a floxed Mecp2 allele 4 to the same hGFAPcreT2 Fig. 7c, trace 3) . b, Respiratory irregularity scores and apnoea rates for male mice. c, Same as in b except for female mice. Mice showing at least 1 apnoea per hour were considered for apnoea rates. All error bars indicate s.e.m. *P , 0.05, **P , 0.01, ***P , 0.001. NS, not significant. The number of mice analysed is indicated above each bar. Fig. 10a, b) . The knockout progeny displayed some phenotypes shared with null Mecp2 mice, such as smaller body size, clasped hindlimb posture and irregular breathing ( Supplementary Fig.  10c, d, f) , but their lifespans, locomotion (data not shown) and anxietyrelated behaviours were all normal ( Supplementary Fig. 10e ). Furthermore, loss of MeCP2 from astrocytes did not affect the number of CA1 apical dendritic branches (Supplementary Fig. 10g ). This indicates that loss of MeCP2 in astrocytes at postnatal day 21 is unable to disrupt the already established hippocampal neuronal circuitry. In contrast, loss of MeCP2 from astrocytes and gain of MeCP2 in astrocytes resulted in a strong non-cell-autonomous influence on breathing pattern. Thus, distinct neuronal-glia interactions may underlie hippocampal and hindbrain breathing circuitries.
Our results indicate that RTT involves impairments in both neurons and glia. In familial amyotrophic lateral sclerosis 28 , neurons and glia are proposed to have different roles in the disease process, with neurons primarily initiating the disease and astrocytes primarily affecting disease progression. Our results are compatible with this model, because removal of MeCP2 just from astrocytes, at postnatal day 21, results in a subtler phenotype than the global null, and re-expression in astrocytes mainly stabilizes symptoms. Along these lines, the appearance of a subset of phenotypes after embryonic removal of MeCP2 from subsets of neurons 4,6-8,10,29 could be explained by causing disease initiation, and prevention of RTT-like phenotypes after Mecp2 reexpression in embryonic neurons 9 could be interpreted as preventing disease initiation. None of these studies addresses whether it could take both MeCP2-deficient neurons and glia to cause disease progression, or whether other non-neuronal cell types, including other glia types, might be involved in the disease process.
Although impaired neurons ultimately underlie nervous system failure in RTT, restoring MeCP2 in glia can ameliorate four consistent and robust features of mouse models of RTT: premature lethality, aberrant respiration, hypoactivity and decreased dendritic complexity. Future studies identifying the key molecules that are restored after glia Mecp2 re-expression may provide further clues into the mechanism of recovery, thereby providing new potential targets for therapeutic intervention.
METHODS SUMMARY
Male mice harbouring an hGFAPcreERT2 transgene were crossed to female Mecp2 1/Stop or Mecp2 1/Jaenisch.Flox mice and the F 1 progeny were injected with 100 mg kg 21 tamoxifen or oil when appropriate. Mice used in astrocyte-rescue experiments were backcrossed for at least seven generations to a C57BL/6 background. Mice used in astrocyte-knockout experiments were of a FVB/N/C57BL/6 background. Histology was performed on transcardially perfused, frozen sections. Behaviour was analysed using CleverSystems StereoScan software. Body plethysmography was performed on unanaesthetized restrained mice. Statistics were performed with Graphpad PRISM V5.0C software. Mouse maintenance, breeding and genotyping, tamoxifen treatments, phenotype scoring, tissue preparation and immunohistochemistry, fluorescence intensity measurements, FACS, plethysmography, motor activity and anxiety assessments, western blotting, and statistics were performed as described in Methods.
Full Methods and any associated references are available in the online version of the paper at www.nature.com/nature. 1/y and hGFAPcreT2 genotypes. The floxed Stop sequence was identified from tail biopsies using the following primers: common 59-AACAGTGCCAGCTGCTCTTC-39, WT 59-CTGTATCCTTGGGTCAAGC TG-39, and mutant 59-GCCAGAGGCCACTTGTGTAG-39. The hGFAPcreT2 sequence was identified with the following primers: 59-CAGGTTGGA GAGGAGACGCATCA-39, 59-CGTTGCATCGACCGGTAATGCAGGC-39. Note that this primer set is specific for the hGFAPcre locus and does not recognize other cre loci. The Jaenich floxed Mecp2 genotype for astrocyte knockout was identified using primers 59-CACCACAGAAGTACTATGATC-39 and 59-CTA GGTAAGAGCTCTTGTTGA-39. Tamoxifen treatments. TAM (Sigma) was made fresh weekly by dissolving in 90% sunflower seed oil/10% ethanol solution by bath sonication for 20-30 min at 4 uC with intermittent vortexing. Final concentration of TAM was 20 mg ml
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. Three-to-four-week-old mice were injected intraperitoneally with 100 mg kg 21 with TAM or oil once daily for 8 days. Occasionally mice began to show signs of discomfort during TAM treatments (that is, decreased mobility, increased tremors, dehydration, rough coat, or gasping). In that case, the remaining TAM treatments were given once every 3-4 days until all mice received 8 injections. The longest interval over which TAM was given was 15 days. Additional TAM treatments to symptomatic mice did not rescue survival. Phenotype scoring. Mice were removed from their home cage and placed onto a metal laminar flow hood for observation.
For mobility: 0 5 as wild type; 1 5 reduced movement when compared to wild type, with extended freezing periods or extended delay to movement when first placed on the surface; 2 5 lack of spontaneous movement when placed on the surface.
For gait: 0 5 as wild type; 1 5 hindlimbs spread wider than wild type when ambulating and/or a lowered pelvis when ambulating; 2 5 lack of full strides by hindlimbs resulting in a dragging of hindquarters.
For limb posture: 0 5 hindlimbs splay outward when suspended by the tail; 1 5 one hindlimb is pulled into the body or forelimbs are stiff and splayed outward without motion; 2 5 one hindlimb is pulled into the body and forelimbs are stiff and splayed outward without motion and might form a widened bowl shape or both hindlimbs are pulled into the body with or without abnormal forelimb posture.
For tremor: 0 5 no tremor; 1 5 intermittent mild tremor; 2 5 continuous tremor or intermittent violent tremor.
For general condition: 0 5 shiny coat, clear and opened eyes, normal body stance; 1 5 dull or squinty eyes, dull or ungroomed coat, somewhat hunched stance; 2 5 piloerection, hunched stance. Tissue preparation, immunohistochemistry, cell counts and neuronal soma measurements. Mice were anaesthetized by intraperitoneal injection of Avertin (2-2-2 Tribromoethanol) and killed by transcardial perfusion of 4% parafomaldehyde in phosphate-buffered saline. Brains were post-fixed overnight and then equilibrated in 30% sucrose overnight at 4 uC. Sagittal sections (40 mm) were cut at -20 uC using a cryostat (Leica) and stored at -20 uC. Sections were immunolabelled overnight at 4 uC using the following primary antibodies: rabbit-MeCP2 Appropriate Alexa Fluor secondary antibodies (1:500, Molecular Probes) or Cy5 were used for 1 h at room temperature. DAPI was present in the ProLong Gold Antifade (Invitrogen) mounting reagent. All images were collected on a Zeiss confocal laser scanning LSM 510 microscope and an Olympus confocal laser scanning FW1000 microscope.
MeCP2 expressing cells were identified as follows: nuclei of astrocytes (GFAP Somal diameters of Nissl-stained neurons were determined by averaging the lengths of the long and short axes across the cell body. Long and short axes were perpendicular to each other. Only cells with a clearly visible DAPI-stained nucleus were considered. Every fourth serial section was used. Only after all cell diameters were collected was the genotype of each section revealed to the experimenter.
Golgi staining was performed using the FD Rapid GolgiStaining Kit according to the manufacturer's instructions (FD NeuroTechnologies, catalogue number PK401). Tissue was vibratome sectioned at 200 mm. Hippocampal CA1 pyramidal neuron apical branches were analysed using an inverted bright-field microscope at 320 magnification by two separate experimenters blind to the genotypes.
Neuronal soma VGLUT1 1 puncta were counted in the medulla oblongata under 363 magnification. Only neuronal somas showing VGLUT1 1 staining were considered. The experimenter was blind to the tissue genotypes. Fluorescence intensity measurements. Cells with clear nuclei were identified by DAPI fluorescence. MeCP2 signal for only these cells were considered. MeCP2 signal for this analysis was not amplified. Rather, a Cy2 secondary antibody was used (collected at 505 nm), directed directly against the primary anti-MeCP2 antibody. All images were captured using an AxioCam HRc (Zeiss) at exactly the same exposure. Raw pixel intensities associated with the DAPI and MeCP2 signals were measured separately in Photoshop. The genotypes of the data were revealed to the experimenter only after all data were collected and analysed. FACS and semi-quantitative PCR. Whole brains were dissected from 6-8-weekold mice and tissue was minced in small pieces in pre-cooled dissociation medium (80 mM Na 2 SO 4 , 30 mM K 2 SO 4 , 0.25 mM CaCl 2 , 20 mM glucose, 10 mM MgCl 2 , 0.001% phenol red and 10 mM HEPES pH 7.5). The tissue was dissociated in medium containing 40 U ml 21 papain (Worthington) for 45 min at 37 uC. The tissue was washed twice in dissociation buffer before transferring to deactivation buffer (DMEM, 0.5 mg ml 21 DNase I and 10% FBS). Sequential trituration was carried out using 10-, 5-and 1-ml pipette tips. Debris was allowed to settle for 2 min. Supernatant was filtered through a 40 mm cell strainer before cells were harvested at 1,000 r.p.m. for 10 min at 4 uC and re-suspended in Dulbecco's PBS (DPBS). To fix, cells were treated with 1% formaldehyde for 15 min at 25 uC. Cells were washed twice with DPBS and then permeabilized in buffer (PBS, 0.2% Triton X-100 and 10% FBS) for 30 min at 25 uC. To identify the NeuN 1 cells in the preparation, cells were probed with anti-mouse NeuN antibody for 30 min at 25 uC. Preparation was probed with anti-mouse IgG-Alexa-488 secondary antibody (Invitrogen). Cells were washed twice with PBS containing 0.2% Triton X-100 before re-suspending in DPBS. To sort the cells using FACS, cells were again passed through a 40 mm filter and subjected to FACS. The sorted cells were collected at 8,000 r.p.m. for 10 min and genomic DNA was prepared from NeuN 1 and NeuN 2 fractions using the QIAamp DNA kit (Qiagen). Genomic PCR for the Mecp2 locus was carried out using the following oligonucleotides: forward MECP2-U2 59-GTTCAGAATCAGGGGAGCAGCCC-39 and reverse upexIII-R3 59-CCTTGGGTCAAGCTGGGGCC-39. For genomic PCR of the b-actin promoter, the following oligonucleotides were used: forward 59-CCCAACACACCT AGCAAATTAGAACCAC-39 and reverse 59-CCTGGATTGAATGGACAGAG AGTCACT-39. PCR products were analysed on a 1% ethidium-bromide-stained agarose gel. Plethysmography. Respiratory parameters were determined in a body plethysmograph. Individual unanaesthetized animals were placed in a 65-ml chamber with their head exposed through a close-fitting hole in parafilm. A pneumotachograph was connected to the chamber and a differential pressure transducer (Model PT5A, Grass Instrument). The pressure signal was integrated to give tidal volume. Volume changes were calibrated by injecting known amounts of air into the chamber. The analogue signal from the transducer was amplified, converted to digital, displayed on a monitor, and stored to disk by computer for later analysis. Apnoea was defined as an expiratory time of 1.0 s or greater. Irregularity score was determined from: absolute (T TOT n 2 T TOT n 1 1)/(T TOT n 1 1). Motor activity and anxiety assessment. Motor activity and anxiety tests were carried out at the same time of day (12.00 to 18.00) and in the same dedicated observation room. Mice were placed singly into an observation box, which was akin to a new home cage, for a total of 20 min, or a standard open field box for 20 min with side-viewing and top-viewing cameras (Clever Systems), or an elevated Zero maze for 5 min with top-viewing cameras (Clever Systems). Mice were allowed to acclimatize to the observation box for the first 10 min and the next 10 min of recording was analysed on a Dell computer. Activity traces were LETTER RESEARCH
